Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

• Verfasst von: Vandenberghe, Rik [VerfasserIn]
• Verfasst von: Gass, Achim [VerfasserIn]
• Titel: Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
• Verf.angabe: Rik Vandenberghe, Juha O. Rinne, Mercè Boada, Sadao Katayama, Philip Scheltens, Bruno Vellas, Michael Tuchman, Achim Gass, Jochen B. Fiebach, Derek Hill, Kasia Lobello, David Li, Tom McRae, Prisca Lucas, Iona Evans, Kevin Booth, Gerald Luscan, Bradley T. Wyman, Lisa Hua, Lingfeng Yang, H. Robert Brashear, Ronald S. Black and for the Bapineuzumab 3000 and 3001 Clinical Study Investigators
• E-Jahr: 2016
• Jahr: 12 May 2016
• Umfang: 13 S.
• Fussnoten: Gesehen am 20.05.2019
• Titel Quelle: Enthalten in: Alzheimer's research & therapy
• Ort Quelle: London : BioMed Central, 2009
• Jahr Quelle: 2016
• Band/Heft Quelle: 8(2016) Artikel-Nummer 18, 13 Seiten
• ISSN Quelle: 1758-9193
• DOI: doi:10.1186/s13195-016-0189-7
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1665952989

Abstract

Background: Our objective was to evaluate the efficacy (clinical and biomarker) and safety of intravenous bapineuzumab in patients with mild to moderate Alzheimer’s disease (AD). Methods: Two of four phase 3, multicenter, randomized, double-blind, placebo-controlled, 18-month trials were conducted globally: one in apolipoprotein E ε4 carriers and another in noncarriers. Patients received bapineuzumab 0.5 mg/kg (both trials) or 1.0 mg/kg (noncarrier trial) or placebo every 13 weeks. Coprimary endpoints were change from baseline to week 78 on the 11-item Alzheimer’s Disease Assessment Scale-Cognitive subscale and the Disability Assessment for Dementia. Results: A total of 683 and 329 patients completed the current carrier and noncarrier trials, respectively, which were terminated prematurely owing to lack of efficacy in the two other phase 3 trials of bapineuzumab in AD. The current trials showed no significant difference between bapineuzumab and placebo for the coprimary endpoints and no effect of bapineuzumab on amyloid load or cerebrospinal fluid phosphorylated tau. (Both measures were stable over time in the placebo group.) Amyloid-related imaging abnormalities with edema or effusion were confirmed as the most notable adverse event. Conclusions: These phase 3 global trials confirmed lack of efficacy of bapineuzumab at tested doses on clinical endpoints in patients with mild to moderate AD. Some differences in the biomarker results were seen compared with the other phase 3 bapineuzumab trials. No unexpected adverse events were observed.